In the subgroups receiving systemic therapy only, the shortest mOS was seen among BRAF-V600Emt/pMMR rectal cancers (6 months) and the longest among RAS&BRAFwt/pMMR rectal cancers (23 months). This evidence concerns the gene BRAF and rectal cancer.